Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEADERSHIP 301 trial of AQX-1125 in interstitial cystitis/bladder pain syndrome
NL-OMON45365Phase 3Active, not recruiting
- Sponsor
- Aquinox Pharmaceuticals
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AQX-1125 in Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS) (3 arms), sponsored by Aquinox Pharmaceuticals. Primary endpoint: Change from baseline to Week 12 in maximum daily bladder pain score. Started Nov 2017; status: active, not recruiting.
02
Drugs
AQX-1125
03
Conditions
Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS)
Beyond the preview
Go deeper on NL-OMON45365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45365.